PPAR-γ Gene Expression in Human Adipose Tissue Is Associated with Weight Loss After Sleeve Gastrectomy

Jorge-Luis Torres1,2 · Ricardo Usategui-Martín3,4 · Lourdes Hernández-Cosido5,6 · Edgar Bernardo7 · Laura Manzanedo-Bueno1,2 · Ignacio Hernández-García8 · Ana-Maria Mateos-Díaz1 · Orlando Rozo9 · Nuria Matesanz7 · Daniel Salete-Granado6 · Antonio-Javier Chamorro1,6 · Cristina Carbonell1,6 · Marina García-Macia1,10,11 · Rogelio González-Sarmiento12 · Guadalupe Sabio7 · Luis Muñoz-Bellvis13 · Miguel Marcos1,6

Received: 5 September 2021 / Accepted: 25 November 2021 / Published online: 8 December 2021
© The Author(s) 2021

Abstract

Background The peroxisome proliferator-activated receptor (PPAR)-γ plays a key role in adipose tissue differentiation and fat metabolism. However, it is unclear which factors may regulate its expression and whether obese patients have changes in adipose tissue expression of PPAR-γ or potential regulators such as miR-27. Thus, our aims were to analyze PPAR-γ and miR-27 expression in adipose tissue of obese patients, and to correlate their levels with clinical variables.

Subjects and Methods We included 43 morbidly obese subjects who underwent sleeve gastrectomy (31 of them completed 1-year follow-up) and 19 non-obese subjects. mRNA expression of PPAR-γ1 and PPAR-γ2, miR-27a, and miR-27b was measured by qPCR in visceral and subcutaneous adipose tissue. Clinical variables and serum adipokine and hormone levels were correlated with PPAR-γ and miR-27 expression. In addition, a systematic review of the literature regarding PPAR-γ expression in adipose tissue of obese patients was performed.

Results We found no differences in the expression of PPAR-γ and miR-27 in adipose tissue of obese patients vs. controls. The literature review revealed discrepant results regarding PPAR-γ expression in adipose tissue of obese patients. Of note, we described a significant negative correlation between pre-operative PPAR-γ1 expression in adipose tissue of obese patients and post-operative weight loss, potentially linked with insulin resistance markers.

Conclusion PPAR-γ1 expression in adipose tissue is associated with weight loss after sleeve gastrectomy and may be used as a biomarker for response to surgery.

Keywords Obesity · PPAR gamma · Bariatric surgery · miR-27

Introduction

The pathogenesis of obesity involves the interaction of behavioral, environmental, and genetic factors 1, which finally results in increased adipose tissue mass due to both adipocyte hypertrophy and hyperplasia, and adipose tissue dysregulation 2,3. Further, obesity is associated with altered adipocyte endocrine signaling, which is a key factor in the pathophysiology of obesity-related complications such as insulin resistance or type 2 diabetes mellitus 4. The worldwide prevalence of obesity has reached epidemic proportions, increasing between 1975 and 2018 from 4.8 to 12.8% in adults over 18 years 5.

Among the several factors involved in adipose tissue regulation, peroxisome proliferator activated receptor (PPAR)-γ, which is highly expressed in white and brown adipose tissue, is considered the “master regulator” of adipogenesis. This transcription factor is a well-characterized regulator of energy metabolism 6 and is clearly involved in the pathophysiology of obesity 6–8 and related complications 9,10. Previous studies, however, have shown conflicting
results regarding PPAR-γ expression in adipose tissue of obese patients. Whereas some studies have shown increased expression of PPAR-γ1, PPAR-γ2, or total PPAR-γ in adipose tissue of obese individuals versus controls, other authors have shown decreased expression of these factors, or no changes whatsoever. Different hypotheses have been tested for these discrepant results, including potential differences related to variables such as gender, the degree of insulin sensitivity, the type of adipose tissue analyzed, or the presence of recent weight loss or gain. Despite these research efforts, the exact role of adipose tissue PPAR-γ gene expression in human obesity remains elusive. In addition, accumulated evidence has shown an important role of several miRNAs in the pathophysiology of obesity, including adipogenesis, insulin resistance, and inflammation. Indeed, recent studies have found that miR-27, mainly miR-27a, regulates the PPAR-γ pathway. This miRNA represses PPAR-γ in human multipotent adipose-derived stem cells and inhibits PPAR-γ gene expression at both the mRNA and protein levels. In this scenario, the main aim of this work was to analyze the expression of PPAR-γ and miR-27 in abdominal and subcutaneous adipose tissue to analyze their potential associations with clinical and metabolic variables of obese patients, including weight loss after surgery. In addition, and due to prior controversial findings, we also performed a systematic review on this topic.

Subjects and Methods

Subjects

The study population was composed of 43 morbidly obese subjects who underwent laparoscopic sleeve gastrectomy. The control group consisted of 19 non-obese subjects who underwent elective laparoscopic cholecystectomy. All individuals were operated by the same surgical team. Obese patients were followed up after surgery at 1, 3, 6, and 12 months (31 patients completed follow-up at least 1 year after surgery). Diagnosis of obesity was established according to the World Health Organization (WHO) criteria. Demographic, anthropometric, laboratory, and clinical characteristics such as age, sex, height, weight, hypertension, diabetes mellitus, cardiovascular disease, dyslipidemia, obstructive sleep apnea–hypopnea syndrome (OSAHS), hypothyroidism, prior cancer, fasting plasma glucose, total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were collected for each subject in the study. Individuals were not receiving PPAR-γ agonists (thiazolidinediones). Body mass index (BMI) and body fat percentage were calculated before surgery and percentage of BMI reduction (100 – [BMI after surgery/initial BMI] *100) and percentage of body weight loss ([number of kilogram lost after surgery/initial weight] * 100) were calculated during follow-up. All subjects were Caucasian.

Ethics Declarations

The experimental protocol was approved by the Ethics Committee of our University Hospital, and it complied fully with the Declaration of Helsinki (2008). All subjects were informed of the purpose of the study and gave written informed consent before inclusion.

Sample Processing and RNA Extraction

A venous sample was taken by venipuncture between 8 a.m. and 11 a.m. after 8 h of fasting, and the serum was immediately frozen at –20 °C prior to testing. Adipose tissue biopsies were taken from abdominal subcutaneous fat and visceral fat at the beginning of the surgical procedure. Adipose tissue specimens were submerged in RNA stabilizing solution (RNAlater, Ambion) and stored at –80 °C until RNA extraction, which was performed using Trizol reagent (Invitrogen) according to the manufacturer’s protocol. RNA quantity and purity were determined by absorbance at 260 nm and 280 nm in a spectrophotometer. The integrity of the RNA was also examined with the Agilent 2100 Bioanalyzer system.

Reverse Transcription and Real-Time Quantitative PCR

For mRNA expression analysis, complementary DNA (cDNA) was synthesized by reverse transcription using a commercial High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer’s manual. Relative quantitative real-time polymerase chain reaction (qPCR) was performed using SYBR Green PCR master mix (Applied Biosystems) and gene-specific primer sets (Supplementary table 1). For reverse transcription of total RNA containing miRNA, a primer specific kit was used (miRCURY LNA Universal RT microRNA PCR, Exiqon), and miRNA expression was performed by qPCR using miRNA-specific primers (Supplementary table 1) and ExiLENT SYBR Green master mix, both from Exiqon. The qPCR experiments were performed in duplicate on a StepOnePlus™ Real-Time PCR System (Applied Biosystems), and primer specificity was verified by melt curve analysis. Threshold cycle (Ct; number of cycles to reach threshold of detection) was determined for each reaction, and gene expression was quantified using the 2−ΔΔCt method.
Evaluation of Reference Genes for Normalization

To select suitable endogenous controls, the stability of expression of each potential reference gene was statistically analyzed with NormFinder [37], GeNorm [38], and BestKeeper [39] algorithms, which allow for the identification of the best reference genes for data normalization. For NormFinder and GeNorm, the GenEX (MultiD) software was used, and for BestKeeper, freely available Microsoft Excel-based software packages were employed [40]. The selection of candidate endogenous controls for mRNA and for miRNA was performed separately, using two different sets of genes (Supplementary table 1). The candidate endogenous control genes for mRNA qPCR were actin, GAPDH, 36B4, and POLR2A. For miRNA normalization, the candidate endogenous gene controls were miR-103a-3p, miR-24-3p, and U6.

Adipokine and Hormone Assays

Multiplex Human Metabolic Hormone Magnetic Bead Panel (HMHEMAG-34 K) and Human Adipokine Magnetic Bead Panel (HADK1MAG-61 K) were used to analyze serum levels of insulin, C-peptide, glucagon, adiponectin, resistin, ghrelin, glucagon-like-peptide-1 (GLP-1), interleukin (IL)-6, and leptin. Analysis was performed according to the manufacturer’s instructions. Insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR or HOMA model: fasting glucose * fasting insulin).

Statistical Analysis

Quantitative variables were expressed as the mean (standard deviation [SD]), while qualitative variables were expressed as the absolute (n) and relative (%) frequencies. Differences among clinical and laboratory data between groups were assessed by the Mann–Whitney test (quantitative variables) and χ² test (qualitative variables). Spearman’s rho (ρ) test was used to analyze the correlation between quantitative variables. Statistical analyses were performed using IBM SPSS Statistics version 25. A P value < 0.05 was regarded as significant.

Bibliographic Search and Systematic Review

A systematic review of the literature was conducted in order to identify case–control studies that assessed mRNA expression of PPAR-γ in adipose tissue in obese patients compared to controls. All studies published before December 2020 were identified by searching the MedLine (source PubMed), Scopus, and Embase (which includes conference abstracts) databases, using the following entries as a search criterion in humans: “PPAR-γ mRNA expression,” “adipose tissue,” and “obesity.” The search was supplemented by reviewing references of original research reports and review articles on the topic. The language was restricted to English, and the search was supplemented using the MedLine option “Related Articles.” After the relevant studies were identified and selected, a standardized set of information was collected from each article including: the name of the authors, the year of publication, the journal of publication, the characteristics of the sample, the study design, the reference gene, and the result. This procedure was carried out according to the recommendations of the PRISMA Statement [41]. Bibliographic search and data extraction were performed independently by three researchers (JLT, RUM, and IHG). Disagreements were resolved by consensus after consulting with another author (AJC).

Results

Analysis of the Basal Characteristics of Subjects Included

Our study included 43 obese subjects (34 women and 9 men) with a mean age of 44.9 (12.2) years old, a BMI of 49.3 (7.5) kg/m², and a body fat percentage of 54.33 (3.83). In addition, 19 non-obese subjects (11 women and 8 men) were included with a mean age of 55.3 (17.4) years old, a BMI of 24.4 (2.1) kg/m², and a body fat percentage of 31.46 (7.22). The basal characteristics of the subjects included in the study and the comparison between obese and non-obese subjects are summarized in Table 1. The only significant differences were that obese patients had higher BMI and body fat percentage and higher prevalence of obstructive sleep apnea–hypopnea syndrome.

PPAR-γ1, PPAR-γ2, miR-27a, and miR-27b Expression in Subcutaneous and Visceral Adipose Tissue

The results of the evaluation of reference genes for normalization used in the analysis of mRNA expression in subcutaneous and visceral adipose tissue showed that actin and miR-103a-3p were the most stable reference genes (Supplementary Fig. 1). Thus, they were used for normalization of the expression of PPAR-γ1, PPAR-γ2, miR-27a, and miR-27b. Results regarding relative mRNA expression of PPAR-γ1 and PPAR-γ2 in subcutaneous and visceral adipose tissue of obese and non-obese subjects are shown in Fig. 1A. No significant differences were found in PPAR-γ1 and PPAR-γ2 mRNA expression in either tissue for the overall group. However, as shown in Fig. 1B, mRNA expression of PPAR-γ1 in visceral adipose tissue was significantly downregulated in obese women.
compared to non-obese women (fold increase = 1.43 vs. 2.27, respectively; \( P = 0.045 \)). A non-significant downregulation was found for this comparison when we separately analyzed women 45 years or younger (fold increase = 1.32 vs. 3.04; \( P = 0.08 \)) or women older than 45 years (fold increase = 1.54 vs. 1.84; \( P = 0.42 \)). A non-significant trend was observed in subcutaneous adipose tissue (fold increase = 1.02 vs. 1.78; \( P = 0.084 \)).

PPAR-γ2 mRNA levels did not significantly differ between obese and non-obese women (data not shown), and the comparison was not performed in male obese patients due to the small sample size. In addition, the mRNA expression of PPAR-γ1 in visceral adipose tissue was negatively correlated with weight (\( \rho = -0.305, P = 0.016 \)) and BMI, (\( \rho = -0.325, P = 0.001 \)). There were no significant correlations between PPAR-γ1 in subcutaneous tissue and PPAR-γ2 in both adipose tissues with weight or BMI. Age was not significantly correlated with PPAR-γ1 or PPAR-γ2 expression. Due to the potential relationship between PPAR-γ and miR-27, we assessed the expression of miR-27a and miR-27b in subcutaneous and visceral adipose tissues, which did not differ between obese and non-obese subjects (Fig. 2). No sex-related differences were found in microRNA expression (data not shown). The results did not show any relationship between microRNA expression and anthropometric variables.

### Correlation Between PPAR-γ and miR-27 Gene Expression

The results showed a positive correlation between PPAR-γ1 and PPAR-γ2 expression in both adipose tissues (visceral adipose tissue: \( \rho = 0.398, P = 0.001 \); and subcutaneous adipose tissue: \( \rho = 0.286, P = 0.024 \)). The results also showed a positive association between the expression of miR-27a and miR-27b in visceral adipose tissue (\( \rho = 0.399, P = 0.001 \)). The expression of PPAR-γ1 and PPAR-γ2 did not significantly correlate with the expression of miR-27a and miR-27b.

### Association Between Gene Expression and Weight Loss After Surgery

Thirty-one patients (72%) were followed-up at least 1 year after surgery. The mean percentage of weight loss and percentage of BMI reduction were of 33.65% (7.7) and 33.64% (7.7), respectively. The relationship between the baseline PPAR-γ1, PPAR-γ2, miR-27a, and miR-27b expression, and weight loss and BMI reduction after surgery were analyzed. The results showed a significant negative correlation between the expression of PPAR-γ1 in subcutaneous and visceral adipose tissues, and the percentage of weight lost (in subcutaneous adipose tissue: \( \rho = -0.404, P = 0.024 \) and in

---

**Table 1** Basal characteristics of the obese and non-obese subjects

|                         | Obese subjects | Non-obese subjects | \( P \) |
|-------------------------|----------------|--------------------|--------|
| Age (years)             | 44.9 (12.3)    | 55.3 (17.4)        | 0.054  |
| Male (n)/Female (n)     | 9/34           | 8/11               | 0.085  |
| BMI (kg/m²)             | 49.3 (7.5)     | 24.4 (2.1)         | <0.001 |
| Hypertension, n (%)     | 18 (41.9)      | 6 (31.6)           | 0.444  |
| Diabetes mellitus, n (%)| 8 (18.6)       | 2 (10.5)           | 0.425  |
| Cardiovascular disease, n (%) | 2 (4.7) | 0           | 0.339  |
| Dyslipidemia, n (%)     | 12 (27.9)      | 3 (15.8)           | 0.304  |
| Hypothyroidism, n (%)   | 8 (18.6)       | 2 (10.5)           | 0.425  |
| OSAHS, n (%)            | 25 (58.1)      | 1 (5.2)            | <0.001 |
| Prior cancer, n (%)     | 2 (4.7)        | 0                  | 0.339  |
| Fasting plasma glucose (mg/dL) | 102.9 (32.1) | 91.1 (12.4)    | 0.061  |
| Total cholesterol (mg/dL) | 197.4 (37.2) | 197.9 (50.1)    | 0.880  |
| Triglycerides (mg/dL)   | 134.9 (59.3)   | 120.6 (54.5)      | 0.551  |
| LDL cholesterol (mg/dL) | 117.5 (37.6)   | 123.8 (41.9)      | 0.733  |
| HDL cholesterol (mg/dL) | 48.1 (11.1)    | 50 (16.6)         | 0.985  |
| Body fat percentage (%) | 54.33 (3.83)   | 31.46 (7.22)      | <0.001 |

Quantitative variables are presented as mean (standard deviation), and qualitative variables are presented as n (%)

*BMI* body mass index, *LDL* low-density lipoprotein, *HDL* high-density lipoprotein, *OSAHS* Obstructive sleep apnea–hypopnea syndrome
visceral adipose tissue: \( \rho = -0.460, P = 0.009 \) (Fig. 3A, B) and percentage of BMI reduction (in subcutaneous adipose tissue: \( \rho = -0.398, P = 0.026 \) and in visceral adipose tissue: \( \rho = -0.462, P = 0.009 \)). In addition, the patients who lost more than 33% of bodyweight had significantly decreased levels of PPAR-\( \gamma \)1 expression compared to patients who lost less than 33% of bodyweight (Fig. 3C). The results also showed a significant negative correlation between the expression of PPAR-\( \gamma \)1 in subcutaneous adipose tissues and the percentage of body fat loss (\( \rho = -0.367, P = 0.042 \)).

Fig. 1 Relative mRNA expression in adipose tissue of obese patients and controls. A) PPAR-\( \gamma \)1 and PPAR-\( \gamma \)2 mRNA expression in visceral and subcutaneous adipose tissue in non-obese (\( n = 19 \)) and obese (\( n = 43 \)) subjects. B) PPAR-\( \gamma \)1 mRNA expression in non-obese women (\( n = 11 \)) and obese women (\( n = 34 \)). Results are expressed as a fold-change relative to the control group (AU: arbitrary unit; mean \( \pm \) SEM; * \( P < 0.05 \)).

Fig. 2 Relative miRNA expression in adipose tissue of obese patients and controls. miR-27a-3p and miR-27a-3p miRNA expression in visceral and subcutaneous adipose tissue in non-obese (\( n = 19 \)) and obese (\( n = 43 \)) subjects. Results are expressed as a fold-change relative to the control group (AU: arbitrary unit; mean \( \pm \) SEM).
The expression of miR-27a in subcutaneous adipose tissue also was associated with the percentage of lost body fat ($\rho = 0.407$, $P = 0.023$). The remaining mRNA and microRNA gene expression data did not show any significant correlations with the decrease in weight and BMI after surgery. Among obese women, the results also showed a negative correlation between PPAR-γ1 expression in adipose tissue and the percentage of weight lost at 12 months (in subcutaneous adipose tissue: $\rho = -0.415$, $P = 0.035$ and in visceral adipose tissue: $\rho = -0.497$, $P = 0.01$).

**Study of the Serum Adipokine and Hormone Levels**

The relationship between the serum adipokine and hormone levels among obese and non-obese subjects is summarized in Table 2. These results showed that the serum levels of C-peptide, insulin, leptin, and HOMA-IR were higher in obese subjects than in non-obese (Table 2). Correlation analysis of the serum adipokine and hormone levels with gene expression in visceral and subcutaneous adipose tissue showed a significant direct correlation between the PPAR-γ1 expression in visceral adipose tissue and serum levels of GLP-1 ($\rho = 0.358$, $P = 0.032$). Among obese women, PPAR-γ1 expression in subcutaneous adipose tissue positively correlated with serum levels of insulin ($\rho = 0.424$, $P = 0.017$), leptin ($\rho = 0.434$, $P = 0.01$), and HOMA-IR ($\rho = 0.410$, $P = 0.022$), and PPAR-γ1 expression in visceral adipose tissue negatively correlated with adiponectin ($\rho = -0.347$, $P = 0.044$).

The correlation between serum adipokine and hormone levels with the rest of variables was also analyzed. Most relevant results showed that obese patients had a significant correlation between the leptin levels and the body fat percentage ($\rho = 0.326$, $P = 0.037$) and between HOMA-IR

---

**Table 2** Serum adipokine and hormone levels in obese and non-obese subjects

|          | Obese subjects $n=43$ | Non-obese subjects $n=19$ | $P$  |
|----------|-----------------------|---------------------------|------|
| C-peptide (pg/mL) | 2366.18 (1205.27) | 1495.23 (1331.39) | 0.001 |
| Insulin (pg/mL) | 996.79 (2875.66) | 273.52 (383.82) | 0.002 |
| Glucagon (pg/mL) | 9.22 (2.75) | 8.1 (2.86) | 0.056 |
| GLP-1 (pg/mL) | 23.41 (32.72) | 69.93 (131.48) | 0.620 |
| IL-6 (pg/mL) | 11.19 (13.41) | 7.66 (3.82) | 0.101 |
| Ghrelin (pg/mL) | 8.14 (3.78) | 10.07 (15.76) | 0.441 |
| Leptin (ng/mL) | 25.31 (12.19) | 3.62 (4.04) | <0.0001 |
| Resistin (ng/mL) | 163.67 (113.06) | 152.02 (109.83) | 0.663 |
| Adiponectin (ng/mL) | 312.93 (102.52) | 339.7 (130.84) | 0.094 |
| HOMA-IR | 2.98 (2.55) | 1.16 (1.38) | 0.003 |

Quantitative variables are presented as mean (standard deviation), and qualitative variables are presented as n (%).

GLP-1 glucagon-like-peptide-1, IL-6 interleukin-6
and serum levels of triglycerides ($\rho = 0.408, P = 0.017$) and HDL-cholesterol ($\rho = -0.459, P = 0.006$). Among obese women, a similar correlation of HOMA-IR with triglycerides and HDL-cholesterol was found. Of note, insulin levels in this subgroup were negatively correlated with percentage of total weight lost at 12 months ($\rho = -0.424, P = 0.044$) and percentage of BMI reduction at 12 months ($\rho = -0.424, P = 0.044$).

### Systematic Review of the Expression of PPAR-γ in Adipose Tissue

Among the published articles that analyzed adipose tissue mRNA expression of PPAR-γ gene in obese patients compared to controls, 24 studies were finally selected for inclusion (Supplementary Fig. 2). As shown in Table 3, three papers have analyzed the expression of PPAR-γ (PPAR-γ1, PPAR-γ2, or the common variant PPAR-γ) only in visceral adipose tissue, eleven in subcutaneous adipose tissue, and ten in both visceral and subcutaneous adipose tissue. To summarize, these papers have produced conflicting results: twelve previous studies have shown an increased mRNA expression of this transcription factor, eight studies have reported a decreased expression, and four studies have found no differences (Table 3). Of note, sample size in most studies is very small, especially regarding the number of controls. In addition, selection criteria of cases and controls differ between studies, with potentially relevant differences in variables such as age or BMI.

### Discussion

In our study, we have analyzed PPAR-γ and miR-27 gene expression in adipose tissue of obese patients, and we have not found clear differences between mRNA PPAR-γ1 or PPAR-γ2 expression in subcutaneous or visceral adipose tissue of obese patients compared with non-obese subjects, apart from a significant decrease only in women. We have also found rather discrepant results between previous studies analyzing this relationship. Among the several factors that may explain these conflicting findings, we should consider that an important number of variables may impact the analysis of PPAR-γ expression. Among them, we can include methodological variations such as the use of different reference genes. In this sense, multiple previous studies had used 18S gene which has been shown as one of the less stable reference genes in adipose tissue of obese patients. Other important variable which could impact PPAR-γ expression is the different characteristics between obese and non-obese subjects (e.g., age or gender or the type of adipose tissue analyzed), since PPAR-γ expression has been shown to differ in human adipocytes from subcutaneous superficial layer compared with deep layer adipocytes. Regrettably, between-study heterogeneity and small sample sizes make it difficult to analyze or confirm the role of any of these variables in PPAR-γ expression in adipose tissue as well as to compare with our own results. In our sample, age did not correlate with PPAR-γ expression although some previous data points towards a diminished PPAR-γ expression among older individuals.

It is of interest, however, that metabolic variables such as degree of insulin sensitivity have been previously associated to changes in miR-27 and PPAR-γ expression. Indeed, the development of peripheral insulin resistance and metabolic syndrome in some patients with obesity is related to the abnormal accumulation of triglycerides and other lipid species in non-adipose tissues (lipotoxicity), which has been previously linked to decreased PPAR-γ expression in fat tissue. However, conflicting data from human and experimental studies correlating insulin resistance and PPAR-γ have been reported. First, several human and experimental studies point out that stimulation of the PPAR-γ receptor has positive effects on insulin resistance, suggesting that this receptor plays a protective role in lipotoxicity. Thus, an inverse correlation between PPAR-γ gene expression in adipose tissue and insulin resistance may exist, and it has also been described that miR-27a repression of PPAR-γ induces insulin resistance. Other authors, however, have found a direct correlation between PPAR-γ in adipose tissue and insulin resistance. The exact role of PPAR-γ in the pathophysiology of adipose tissue in obesity has yet to be elucidated, particularly because two similar studies with PPAR-γ adipose knockout mouse models also have conflicting results. In the study by Jones et al., ablation of PPAR-γ in adipose tissue protected against the development of obesity and insulin resistance following a high fat diet. In contrast, another PPAR-γ knockout mouse model in adipose tissue has shown an increase in insulin resistance in adipose tissue and liver, but not in muscle tissue. These differences have been attributed to the point during development in which genetic recombination occurred that gave rise to the knockout, or to the recombination efficiency, but the findings remain difficult to interpret. In this scenario, we have found several significant correlations between PPAR-γ gene expression and adipokines and hormones, but our results did not show a consistent association across different tissues and groups between miR-27 or PPAR-γ gene expression and markers of insulin resistance. To summarize, although several data suggest that reduced PPAR-γ expression is directly correlated with insulin resistance, our data and results from previous studies do not allow us to reach definite conclusions. This situation along with the conflicting data regarding PPAR-γ expression in adipose tissue hampers the design of mechanistic experiments to address this association.
### Table 3 Previous works analyzing expression of PPAR-γ gene in adipose tissue

| First author, year | Reference genes | Targets genes | Obese (N) | Non-obese (N) | Principal results (compared to controls) |
|--------------------|-----------------|---------------|-----------|---------------|-----------------------------------------|
| Lefebvre et al. 1997 | -               | PPAR-γ1 PPAR-γ2 | 6         | 6             | Increased expression of PPAR-γ in subcutaneous and visceral adipose tissue of obese patients |
| Auboeuf et al. 1997 | -               | PPAR-γ1 PPAR-γ2 | 10        | 10            | No differences in PPAR-γ1 and PPAR-γ2 expression in visceral adipose tissue |
| Vidal-Puig et al. 1997 | 18S            | PPAR-γ1 PPAR-γ2 | 24        | 14            | Increased expression of PPAR-γ2 in subcutaneous adipose tissue of obese patients. Non-significant decreased expression of PPAR-γ1 in obese patients |
| Krempler et al. 2000 | GAPDH and actin | PPAR-γ        | 50/76*    | 19/20*        | No differences in PPAR-γ expression |
| Redonnet et al. 2002 | Actin          | PPAR-γ        | 15        | 10            | Increased expression of PPAR-γ in subcutaneous adipose tissue of obese women |
| Sewter et al. 2002 | GAPDH           | PPAR-γ1 PPAR-γ2 | 11        | 11            | Increased expression of PPAR-γ1 and decreased expression of PPAR-γ2 in subcutaneous adipose tissue of obese patients |
| Bortolotto et al. 2007 | Actin         | PPAR-γ        | 10        | 10            | Increased expression of PPAR-γ in subcutaneous adipose tissue of obese patients, but no differences in visceral adipose tissue |
| Ceperuelo-Mallafre et al. 2007 | Actin       | PPAR-γ        | 35        | 12            | Increased expression of PPAR-γ in subcutaneous adipose tissue of obese patients, but no differences in visceral adipose tissue |
| Miranda et al. 2007 | Actin           | PPAR-γ        | 22        | 24            | No differences in expression of PPAR-γ in subcutaneous adipose tissue of obese patients |
| Poulain-Godefroy et al. 2008 | GAPDH       | PPAR-γ1 PPAR-γ2 | 18        | 6             | Decreased expression of PPAR-γ1 and PPAR-γ2 in subcutaneous adipose tissue of obese women, but not in visceral adipose tissue |
| Macias-Gonzalez et al. 2009 | 18S        | PPAR-γ1 PPAR-γ2 | 26        | 8             | Decreased expression of PPAR-γ2 in visceral adipose tissue of obese patients compared with controls |
| Bairras et al. 2010 | Cyclophilin    | PPAR-γ1 PPAR-γ2 | 32        | 12            | Increased expression of PPAR-γ2 in visceral and subcutaneous adipose tissue of obese patients. No differences in expression of PPAR-γ1 |
| Rodríguez-Acebes et al. 2010 | 36B4     | PPAR-γ1 PPAR-γ2 | 40        | 18            | Decreased expression of PPAR-γ1 in subcutaneous adipose tissue of obese patients, but no differences in expression of PPAR-γ2 |
| Ruschke et al. 2010 | 18S            | PPAR-γ2        | 95        | 58            | Increased expression of PPAR-γ2 in visceral and subcutaneous adipose tissue of obese patients |
| Lee et al. 2010   | GAPDH          | PPAR-γ        | 12        | 5             | Increased expression of PPAR-γ subcutaneous adipose tissue of obese women |
| Koudhi et al. 2011 | 18S            | PPAR-γ        | 7         | 6             | Increased expression of PPAR-γ in obese in subcutaneous adipose tissue of obese patients |
| Hammes et al. 2012 | B2M            | PPAR-γ        | 13        | 10            | No differences in expression of PPAR-γ in subcutaneous and visceral adipose tissue |
In this context, however, it is very interesting that we report for the first time that reduced expression of PPAR-γ1 is associated with more percentage of weight loss and BMI reduction at 1 year after sleeve gastrectomy. This result was consistent in both subcutaneous and visceral adipose tissue and also in the group of obese women (too few obese men were available for reliable statistical comparisons). In order to interpret this finding, we have to consider that sleeve gastrectomy has also a metabolic effect. Indeed, it has been reported that obese patients show improved glucose metabolism and significant hormonal changes after this technique \(^{55}\), and mice who underwent this procedure, compared to those who underwent gastric bands, displayed increased adiponectin and GLP-1 levels, and improved insulin resistance and lipid profile \(^{56}\). Therefore, we may hypothesize that patients with lower PPAR-γ1 expression may be more sensitive to metabolic changes after bariatric surgery, although further studies are needed to confirm this hypothesis. This hypothesis could be reinforced by the fact that, among obese women, basal fasting insulin serum levels, a marker of insulin resistance, were also negatively correlated with weight loss after surgery, and adiponectin levels, a marker of insulin sensitivity, were negatively correlated with PPAR-γ1 expression in visceral adipose tissue \(^{57,58}\). Although we are well aware that the regulation of insulin resistance is far more complex, all our data together might point towards an association of certain markers of insulin sensitivity (reduced PPAR-γ1 expression and decreased insulin serum levels along with increased adiponectin levels) with more weight loss after bariatric surgery. In any case, our clinical data shows that lower PPAR-γ1 expression in adipose tissue could be a marker of better response to sleeve gastrectomy.

Regarding miR-27 gene expression in adipose tissue, we have not confirmed previous results by Viesti et al. \(^{59}\), which showed a higher expression of miR-27a in visceral adipose tissue of obese patients compared to non-obese subjects. Nonetheless, we described that miR-27a expression in adipose tissue was positively correlated with the percentage of body fat loss after sleeve gastrectomy. Since it has been reported that miR-27a inhibits PPAR-γ gene expression \(^{51}\), it would be tempting to speculate that higher levels of miR-27a expression could promote reduced PPAR-γ1 expression in adipose tissue and more weight loss after surgery, but more data are needed to support this hypothesis.

### Conclusion

In summary, obese patients might have changes in PPAR-γ expression in adipose tissue reflecting differences in insulin resistance and other variables such as sex, although these changes compared with controls are not clearly established according to our own results and the systematic review performed. In addition, we described that reduced PPAR-γ expression in adipose tissue is associated with increased weight loss after sleeve gastrectomy and could be a potential biomarker of better response after surgery.

---

**Table 3 (continued)**

| First author, year | Reference genes | Targets genes | Obese (N) | Non-obese (N) | Principal results (compared to controls) |
|--------------------|-----------------|---------------|-----------|---------------|------------------------------------------|
| Leyvraz et al. 2012\(^{19}\) | B2M | PPAR-γ1 PPAR-γ2 | 30 | 5 | Decreased expression of PPAR-γ1 in subcutaneous and visceral adipose tissue of obese women, but no difference in expression of PPAR-γ2 |
| Berhouma et al. 2013\(^{11}\) | 18S | PPAR-γ | 262 | 83 | Increased expression of PPAR-γ2 in subcutaneous adipose tissue of obese women |
| Moreno-Navarrete et al. 2013\(^{20}\) | PPIA | PPAR-γ | 25 | 31 | Decreased expression of PPAR-γ in subcutaneous and visceral adipose tissue of obese patients |
| Nuñez-Ruiz et al. 2016\(^{63}\) | 18S | PPAR-γ | 15 | 11 | Decreased expression of PPAR-γ in adipose tissue in obese subjects |
| Martínez-Jiménez et al. 2018\(^{64}\) | GADPH | PPAR-γ | 26 | 24 | Increased expression of PPAR-γ in subcutaneous adipose tissue of obese subjects |
| Boughanem et al. 2019\(^{65}\) | Actin | PPAR-γ2 | 23 | 15 | Decreased expression of PPAR-γ2 in visceral adipose tissue of obese individuals |
| Tryggestad et al. 2019\(^{66}\) | GAPDH | PPAR-γ | 6 | 10 | Decreased expression of PPAR-γ in subcutaneous adipose tissue of obese patients |

\(^{*}\)Sample size for subcutaneous/visceral fat samples
References

1. Lyon HN, Hirschhorn JN. Genetics of common forms of obesity: a brief overview. Am J Clin Nutr. 2005;82(1 Suppl):215S-217S.
2. McGregor RA, Choi MS. microRNAs in the regulation of adipogenesis and obesity. Curr Mol Med. 2011;11(4):304–16.
3. Rosen ED, MacDougall OA. Adipocyte differentiation from the inside out. Nature Reviews Molecular Cell Biology. 2006;
4. Henninger AMJ, Eliasson B, Jenndahl LE, Hammarstedt AD. Adipocytokine hypertrophy, inflammation and fibrosis characterize subcavernous adipose tissue of healthy, non-obese subjects predisposed to type 2 diabetes. PLoS One. 2014;9(9):e105262.
5. Blüher M. Obesity: global epidemiology and pathogenesis. Nature Reviews Endocrinology. 2019;15(5):288–98.
6. Ahmadian M, Suh JM, Hahn N, Liddle C, Atkins AR, Downes M, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5):557–66.
7. Galbete C, Toledo E, Martínez-González MA, Martínez JA, Guillén-Grima F, Martí A. Pro12Ala variant of the PPARγ2 gene increases body mass index: An updated meta-analysis encompassing 49,092 subjects. Obesity (Silver Spring). 2013;21(7):1486–95.
8. Razquin C, Marti A, Martinez JA. Evidences on three relevant obesogenes: MC4R, FTO and PPARα. Approaches for personalized nutrition. Mol Nutr Food Res. 2011;55(1):136–49.
9. Lehre M, Lazar MA. The many faces of PPARgamma. Cell. 2005;123(6):993–9.
10. Videla LA, Pettinelli P. Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. PPAR Res. 2012;2012:107434.
11. Berhouma R, Kouidhi S, Ammar M, Abid H, Ennaffa H, Benamar-Elgaaied A. Correlation of peroxisome proliferator-activated receptor (PPAR-γ) mRNA expression with Pro12Ala polymorphism in obesity. Biochem Genet. 2013;51(3–4):256–63.
12. Bortolotto JW, Margis R, Ferreira ACB, Padoin AV, Mottin CC, Guaragna RM. Adipose tissue distribution and quantification of PPARbeta/delta and PPARgamma1-3 mRNAs: discordant gene expression in subcutaneous, retroperitoneal and visceral adipose tissue of morbidly obese patients. Obes Surg. 2007;17(7):934–40.
13. Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM, Srikanth S, et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol. 2011;31(4):626–38.
14. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes. 1998;47(1):98–103.
15. Redonnet A, Bonilla S, Noël-Suberville C, Pallet V, Dabadie H, Gin H, et al. Relationship between peroxisome proliferator-activated receptor gamma and retinoic acid receptor alpha gene expression in obese human adipose tissue. Int J Obes Relat Metab Disord. 2002;26(7):920–7.
16. Ruschke K, Fischlein L, Dietrich A, Klötting N, Tönjes A, Oberbach A, et al. Gene expression of PPARgamma and PGC-1alpha in human omental and subcutaneous adipose tissues is related to insulin resistance markers and mediates beneficial effects of physical training. Eur J Endocrinol. 2010;162(3):515–23.
17. Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, Werman A, Pories WJ, Caro JF, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997;99(10):2416–22.
18. Koudih S, Jarboui S, Marrakchi R, Froidevaux M-SC, Seugnet I, Abid H, et al. Adiponectin expression and metabolic markers in obesity and Type 2 diabetes. J Endocrinol Invest. 2011;34(2):16-23.
19. Leyvraz C, Verduin C, Suter M, Paroz A, Calmes J-M, Marques-Vidal PM, et al. Changes in gene expression profile in human subcutaneous adipose tissue during significant weight loss. Obes Facts. 2012;5(3):440–51.
20. Moreno-Navarrete JM, Petrov P, Serrano M, Ortega F, García-Ruíz E, Oliver P, et al. Decreased RB1 mRNA, protein, and activity reflect obesity-induced altered adipogenic capacity in human adipose tissue. Diabetes. 2013;62(6):1923–31.
21. Poulain-Godefroy O, Lecoeur C, Pattou F, Frühbeck G, Froguel P. Inflammation is associated with a decrease of lipogenic factors in visceral adipose tissue. Diabetes. 2013;62(6):1923–31.
22. Rodríguez-Acebes S, Palacios N, Botella-Carretero JI, Olea N, Crespo L, Peromingo R, et al. Gene expression profiling of subcutaneous adipose tissue in morbid obesity using a focused microarray: distinct expression of cell-cycle- and differentiation-related genes. BMC Med Genomics. 2010;3:61.
23. Auboef D, Riesset F, Fajas L, Vallier P, Ferring V, Riou JP, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46(8):1319–27.
24. Hammes TO, Costa C dos S, Rohden F, Margis R, de Almeida JC, Padoin AV, et al. Parallel down-regulation of FOXO1, PPARγ and adiponectin mRNA expression in visceral adipose tissue of class III obese individuals. Obes Facts. 2012;5(3):452–9.

25. Krempler F, Breban D, Obergfoller H, Esterbauer H, Hell E, Paulweber B, et al. Leptin, peroxisome proliferator-activated receptor-gamma, and CCAAT/enhancer binding protein-alpha mRNA expression in adipose tissue of humans and their relation to cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20(2):443–49.

26. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes. 1998;47(9):1384–91.

27. Ceperuelo-Mallafrey V, Miranda M, Chacón MR, Villarasa N, Megia A, Gutiérrez C, et al. Adipose tissue expression of the glycero]lcer channel aquaporin-7 gene is altered in severe obesity but not in type 2 diabetes. J Clin Endocrinol Metab. 2007;92(9):3640–5.

28. Miranda M, Chacón MR, Gómez J, Megia A, Ceperuelo-Mallafrey V, Veloso S, et al. Human subcutaneous adipose tissue LPIN1 expression in obesity, type 2 diabetes mellitus, and human immunodeficiency virus–associated lipodystrophy syndrome. Metabolism. 2007;56(11):1518–26.

29. Sato H, Sugai H, Kurosaki H, Ishikawa M, Funaki A, Kimura Y, et al. The effect of sex hormones on peroxisome proliferator-activated receptor gamma expression and activity in mature adipocytes. Biol Pharm Bull. 2013;36(4):564–73.

30. Shea MK, Nicklas BJ, Marsh AP, Houston DK, Miller GD, Isom S, et al. The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypoal- loriwht obesity. Obesity (Silver Spring). 2011;19(8):1636–46.

31. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu C-Y, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39–48.

32. Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, et al. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation. 2004;110(20):3259–69.

33. Karpriener M, Fischer C, Nowitsch S, Opriessng P, Papak C, Aihauud G, et al. microRNA miR-27a impairs human adipocyte differentiation and targets PPARgamma. Biochim Biophys Acta. 2009;1790(2):247–51.

34. Chen T, Zhang Y, Liu Y, Zhu D, Yu J, Li G, et al. MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPARγ-mediated PI3K/AKT signaling. Aging (Albany NY). 2019;11(18):7510–24.

35. Hemmrich K, Denecke B, Paul NE, Hoffmeister D, Pallua N. RNA Isolation from Adipose Tissue: An Optimized Procedure for High RNA Yield and Integrity. Laboratory Medicine. 2010;41(2):104–6.

36. Livak KJ, Schmittden TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(ΔΔC(T)) Method. Methods. 2001;25(4):402–8.

37. Andersen CL, Jensen JL, Ørnoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64(15):5245–50.

38. Vandesonpleme J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.

39. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett. 2004;26(6):509–15.

40. BestKeeper Software - BioInformatics in kinetic PCR [Internet]. [cited 2020 Dec 12]. Available from: https://www.gene-quantification.de/bestkeeper.html.

41. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine. 2009;6(7):e1000097.

42. Hyatt D, Olgac N, Nemec M, Derbel B, Shahinian J, Mistry K, et al. A protocol for identifying microRNAs that are differentially expressed in human adipose tissue: a model-based variance estimation approach to identify genes suited for normalization. Aging Cell. 2010;18(5):897–903.

43. Mehta R, Birerdinc A, Hossain N, Afendy V, Chandhoke V, Younossi Z, et al. Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. BMC Mol Biol. 2010;11:39.

44. Kosaka K, Kubota Y, Adachi N, Akiti S, Sasahara Y, Kira T, et al. Human adipocytes from the subcutaneous superficial layer have greater adipogenic potential and lower PPARγ DNA methylation levels than deep layer adipocytes. Am J Physiol Cell Physiol. 2016;311(2):C322-329.

45. Miard S, Dombrowski L, Carter S, Boivin L, Picard F. Aging alters PPARgamma in rodent and human adipose tissue by modu- lating the balance in steroid receptor coactivator-1. Aging Cell. 2009;8(4):449–59.

46. Ye P, Zhang X-J, Wang Z-J, Zhang C. Effect of aging on the expression of peroxisome proliferator-activated receptor gamma and the possible relation to insulin resistance. Gerontology. 2006:52(2):69–75.

47. Yu Y, Du H, Wei S, Feng L, Li J, Yao F, et al. Adipocyte-Derived Exosomal MiR-27a Induces Insulin Resistance in Skeletal Muscle Through Repression of PPARγ. Theranostics. 2018;8(8):2171–88.

48. Medina-Gomez G, Gray S, Vidal-Puig A. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr. 2007;10(10A):1132–7.

49. Yao F, Yu Y, Feng L, Li J, Zhang M, Lan X, et al. Adipogenic miR-27a in adipose tissue upregulates macrophage activation via inhibiting PPARγ of insulin resistance induced by high-fat diet-associated obesity. Exp Cell Res. 2017;355(2):105–12.

50. Saraf N, Sharma PK, Mondal SC, Gark VK, Singh AK. Role of PPARγ2 transcription factor in thiazolidinedione-induced insulin sensitization. J Pharm Pharmacol. 2012;64(2):161–71.

51. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord. 2003;27(2):147–61.

52. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome—a holistic perspective. Biochim Biophys Acta. 2010;1801(3):338–49.

53. Jones IR, Barrick C, Kim K-A, Lindner J, Blondeau B, Fujimoto Y, et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci U S A. 2005;102(17):6207–12.

54. He W, Barak Y, Heveren A, Olson P, Liao D, Le J, et al. Adipose- specific peroxisome proliferator-activated receptor gamma knock- out causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A. 2003;100(26):15712–7.

55. Dimitriadis E, Daskalakis M, Kampa M, Peppe A, Papadakis JA, Melissas J. Alterations in gut hormones after laparoscopic sleeve gastrectomy: a prospective clinical and laboratory investigational study. Ann Surg. 2013;257(4):647–54.
56. Kawano Y, Ohta M, Hirashita T, Masuda T, Inomata M, Kitano S. Effects of sleeve gastrectomy on lipid metabolism in an obese diabetic rat model. Obes Surg. 2013;23(12):1947–56.

57. Hung J, McQuillan BM, Thompson PL, Beilby JP. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond). 2008;32(5):772–9.

58. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137(9):959–65.

59. Viestri A Collares R, Salgado W, Pretti da Cunha Tirapelli D, dos Santos JS. The expression of LEP, LEPR, IGFI and IL10 in obesity and the relationship with microRNAs. PLoS One. 2014;9(4):e93512.

60. Sewter C, Blows F, Considine R, Vidal-Puig A, O’Rahilly S. Differential effects of adiposity on peroxisomal proliferator-activated receptor gamma1 and gamma2 messenger ribonucleic acid expression in human adipocytes. J Clin Endocrinol Metab. 2002;87(9):4203–7.

61. Macias-Gonzalez M, Moreno-Santos I, García-Almeida JM, Tinañones FJ, Garcia-Fuentes E. PPARγ2 protects against obesity by means of a mechanism that mediates insulin resistance. European Journal of Clinical Investigation. 2009;39(11):972–9.

62. Bairras C, Redonnet A, Dabadie H, Gin H, Atgie C, Pallet V, et al. RARgamma and TRbeta expressions are decreased in PBMC and SWAT of obese subjects in weight gain. J Physiol Biochem. 2010;66(1):29–37.

63. Núñez Ruiz A, Cortés-Garcia JD, Cortez-Espinoso N, Herrera-Rojas PI, Ruiz-Rodriguez VM, Salgado-Bustamante M, et al. Diminished levels of regulatory T cell subsets (CD8+Foxp3, CD4+Foxp3 and CD4+CD39+Foxp3) but increased Foxp3 expression in adipose tissue from overweight subjects. Nutrition. 2016;32(9):943–54.

64. Martínez-Jiménez V, Cortez-Espinoso N, Rodríguez-Varela E, Vega-Cárdenas M, Briones-Espinoza M, Ruiz-Rodriguez VM, et al. Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity. Diabetes Metab Syndr. 2019;13(1):582–9.

65. Boughanem H, Cabrera-Mulero A, Millán-Gómez M, Garrido-Sánchez L, Cardona F, Tinañones FJ, et al. Transcriptional Analysis of FOXO1, C/EBP-α and PPAR-γ2 Genes and Their Association with Obesity-Related Insulin Resistance. Genes (Basel). 2019;10(9).

66. Tryggestad JB, Teague AM, Sparling DP, Jiang S, Chernausek SD. Macrophage-Derived microRNA-155 Increases in Obesity and Influences Adipocyte Metabolism by Targeting Peroxisome Proliferator-Activated Receptor Gamma. Obesity (Silver Spring). 2019;27(11):1856–64.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Jorge-Luis Torres1,2 · Ricardo Usategui-Martín3,4 · Lourdes Hernández-Cosío5,6,7 · Edgar Bernardo7 · Laura Manzanedo-Bueno1,2 · Ignacio Hernández-García8 · Ana-María Mateos-Díaz1 · Orlando Rozo9 · Nuria Matesanz7 · Daniel Salete-Granado6 · Antonio-Javier Chamorro1,6 · Cristina Carbonell1,6 · Marina García-Macía1,10,11 · Rogelio González-Sarmiento12 · Guadalupe Sabio7 · Luis Muñoz-Bellvís13 · Miguel Marcos1,6

1 Department of Internal Medicine, University Hospital of Salamanca-SACYL-IBSAL, Salamanca, Spain
2 Department of Internal Medicine, Complejo Asistencial de Zamora-SACYL, Zamora, Spain
3 IOBA, University of Valladolid, Valladolid, Spain
4 Cooperative Health Network for Research (REITICS), Oftared, National Institute of Health Carlos III, ISCIII, Madrid, Spain
5 Bariatric Surgery Unit, Department of General and Gastrointestinal Surgery, University Hospital of Salamanca, Salamanca, Spain
6 University of Salamanca, Salamanca, Spain
7 Department of Vascular Biology and Inflammation, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, 28029 Madrid, Spain
8 Department of Preventive Medicine and Public Health, Lozano Blesa University Clinical Hospital of Zaragoza, Zaragoza, Spain
9 Department of Surgery, Complejo Asistencial de Ávila-SACYL, Ávila, Spain
10 Institute of Functional Biology and Genomics, University of Salamanca, CSIC, Salamanca, Spain
11 Centro de Investigación Biomédica en Red Sobre Fragilidad Y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain
12 Molecular Medicine Unit-IBSAL, University of Salamanca-SACYL-ICIB, Salamanca, Spain
13 Department of General and Gastrointestinal Surgery, Hospital Universitario de Salamanca, Biomedical Research Institute of Salamanca (IBSAL), Universidad de Salamanca, Salamanca, Spain